Skip to main content
. 2019 Jul 25;11(8):1710. doi: 10.3390/nu11081710

Table 2.

Effects of MiPo supplementation on plasma lipids and glucose concentrations.

Parameter Sample Time (n = 11)
0 h 4 h 8 h
Glucose (mg/dL) Pre 88.3 (76.6–125.9) 83.2 (67.9–113.9) 88.9 (76.3–110.4)
Post 79.7 (73.2–89.0) 88.0 (78.7–95.3) 89.2 (78.2–92.1)
Total cholesterol (mg/dL) Pre 157.6 (146.5–219.8) 150.9 (139.9–245.8) 141.4 (130.2–254.4)
Post 133.2 (87.1–140.7) a 138.9 (127.2–149.0) b 128.4 (103.3–148.6) c
LDL-C (mg/dL) Pre 85.8 (69.1–161.1) 73.4 (56.1–160.4) 74.2 (52.1–180.0)
Post 62.7 (34.1–88.5) a 46.9 (40.6–63.6) b 48.2 (34.2–65.3) c
Triglycerides (mg/dL) Pre 125.4 (119.4–182.3) 226.6 (190.0–344.2) a 202.2 (156.6–322.9) a,b
Post 105.1 (83.5–120.7) a 207.5 (112.5–247.4) b,d 117.2 (92.3–197.9) c,d,e
iAUC (h × mg/dL) Pre 419.0 (315.3–1011.7)
Post 382.8 (107.3–563.0) f
HDL-C (mg/dL) Pre 39.4 (35.7–56.7) 38.0 (31.4–47) a 36.6 (33.2–49.2) a
Post 43.9 (40.2–62.6) a 39.4 (35.8–53.3) d 39.3 (36.8–49.3) c,d
HDL-Tg (mg/dL) Pre 17.0 (14.6–25.5) 20.1 (15.8–28.0) 25.3 (16.3–30.8)
Post 19.8 (19.4–31.4) 22.9 (20.3–30.8) 29.8 (23.9–36.7) c,d,e
HDL-Pho (mg/dL) Pre 89.4 (75.4–115.4) 93.2 (75.4–103.1) 88.6 (72.1–122.0)
Post 95.9 (80.8–113.0) 90.2 (80.0–103.3) 101.6 (91.2–129.3) c,d,e
Ratios:
HDL-C/HDL-Pho Pre 0.489 (0.399–0.559) 0.433 (0.388–0.464) 0.424 (0.388–0.464)
Post 0.460 (0.421–0.595) 0.429 (0.395–0.499) d 0.363 (0.337–0.447) d,e
HDL-Tg/HDL-Pho Pre 0.217 (0.146–0.287) 0.232 (0.166–0.301) 0.259 (0.201–0.339)
Post 0.255 (0.194–0.288) 0.234 (0.201–0.396) 0.278 (0.208–0.375)

Data are expressed as median (interquartile range). Wilcoxon test a p < 0.05 vs. 0 h pre-supplementation. b p < 0.05 vs. 4 h pre-supplementation. c p < 0.05 vs. 8 h pre-supplementation. d p < 0.05 vs. 0 h post-supplementation. e p < 0.05 vs. 4 h post-supplementation. iAUC: Incremental area under the curve. LDL-C: Low-density lipoprotein-cholesterol. HDL-C: High-density lipoprotein-cholesterol. HDL-Tg: HDL-triglycerides. HDL-Pho: HDL-phospholipids.